Logo

CORONA REMEDIES LIMITED Share Price

NSE: CORONA
|
Pharmaceuticals
₹ 2,037.90
+₹28.90 (1.44%)
1D
Last updated 03 Jul, 2026, 15:59 IST

CORONA REMEDIES LIMITED Share Price Today

As of 5 Jul 2026, CORONA REMEDIES LIMITED share price is ₹2,037.90. The stock opened at ₹2,030.00, compared to its previous close of ₹2,009.00. During today's trading session, CORONA REMEDIES LIMITED share price moved in the range of ₹2,030.00 to ₹2,075.90, with an average price of ₹2,052.95 for the day. Looking at its last 52-week, the stock has touched a low of ₹1,336.60 and a high of ₹2,100.70. On the performance front, CORONA REMEDIES LIMITED share price has increased by 41.18% over the last six months and is up 41.68% on a year-on-year basis.

₹2,030.00
1.44% up today
₹2,075.90
1D LOW
1D HIGH

CORONA REMEDIES LIMITED Returns Calculator

Open
₹2,030.00
High
₹2,075.90
Low
₹2,030.00
Prev. close
₹2,009.00
Circuit
L
H
₹1,630.40
₹2,445.40
52-week
L
H
₹1,336.60
₹2,100.70

CORONA REMEDIES LIMITED Shareholder Returns

CORONA REMEDIES LIMITED Share Price History

Mkt Cap Cr
12,287.10
P/E
51.41
P/B
12.74
ROE
27.36%
D/E
0.19
ROCE
28.95%
Div. Yield
0.64%
EPS(TTM)
30.22
Turnover
1.66
EV/EBITDA
33.79
Net Margin
13.17%
Op. Margin
20.31%
ROA
18.93%
Quick Ratio
0.62
Curr. Ratio
1.10
Based on fundamentals, this stock's
Step 5 of 5
Performance
Excellent
Corona Remedies outperforming all market indices
Step 1 of 5
Valuation
Overvalued
Corona Remedies appears overvalued compared to its peers
Step 5 of 5
Earnings
Excellent
Corona Remedies revenue, operating profit and net profit are growing
Peer Comparison
Peer comparison — key ratios
NameMkt Cap CrP/EP/BROED/EROCEBook ValueDiv. YieldTurnoverEPS(TTM)
Sun Pharmaceutical Industries4,49,048.0039.025.3713.74%0.6117.33%93.240.85%0.5610.90
Divis Laboratories1,77,179.0069.0010.5715.32%0.0019.56%629.490.45%0.5898.19
Torrent Pharmaceuticals1,57,804.0066.0317.0326.76%1.0518.30%16.900.90%0.4964.75
Cipla1,17,642.0025.472.8711.79%0.0015.66%2.891.06%0.4943.52
Dr. Reddy's Laboratories1,12,368.0027.032.9711.07%0.1812.54%375.780.59%0.6338.68
Zydus Lifesciences1,10,651.0021.604.0818.59%0.3117.35%235.250.09%0.3935.38
Lupin1,09,676.0020.484.8923.76%0.0424.88%659.050.75%0.61129.18
Mankind Pharma1,02,729.0053.006.3011.74%0.3413.13%397.020.04%0.5449.37
Aurobindo Pharma90,608.0025.872.399.25%0.1911.76%391.140.26%0.4841.58
Laurus Labs82,398.9060.2610.1018.21%0.4516.70%10.190.20%0.9713.72

CORONA REMEDIES LIMITED Financials

Full statement

Income Statement · Consolidated

Income Statement · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Revenue₹1,403.18₹1,196.42₹1,014.47₹884.05
Other Income₹10.65₹5.93₹6.46₹7.05
Total Revenue₹1,413.83₹1,202.35₹1,020.93₹891.10
Total Expenses₹1,154.58₹1,004.20₹902.46₹780.44
Profit Before Tax₹240.42₹198.53₹118.48₹110.89
Tax₹55.30₹49.10₹27.98₹25.96
Profit After Tax₹185.12₹149.43₹90.50₹84.93
EPS - Basic₹30.27₹24.43₹14.80₹14.57
EPS - Diluted₹30.27₹24.43₹14.80₹14.57

Cash Flow · Consolidated

Cash Flow · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Profit before tax₹240.42₹198.53₹118.48₹110.89
Income before WC changes₹284.77₹250.84₹165.35₹133.44
Change in Assets-₹32.73-₹51.80-₹11.87-₹33.63
Change in Liabilities₹26.86₹34.73₹21.19₹28.72
Change in WC-₹5.87-₹17.07₹9.32-₹4.92
Cash flow from Operations₹229.48₹190.49₹156.76₹102.70
Cash flow from Investing-₹256.15-₹83.86-₹266.64-₹50.25
Cash flow from Financing₹25.28-₹106.57₹98.55-₹44.75
Total Cash Flow-₹1.39₹0.06-₹11.34₹7.71
Cash (Start of the year)₹3.22₹3.16₹14.49₹6.82
Cash (End of the year)₹1.83₹3.22₹3.16₹14.49

Balance Sheet · Consolidated

Balance Sheet · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Non-Current Assets₹856.83₹590.99₹540.66₹303.54
Current Assets₹348.31₹338.87₹289.92₹291.49
Total Assets₹1,205.14₹929.86₹830.58₹595.02
Current Liabilities₹361.17₹239.59₹224.19₹137.37
Net Current Asset-₹12.86₹99.28₹65.72₹154.12
Non-Current Liabilities₹97.11₹83.93₹125.98₹49.13
Equity Capital₹746.86₹606.34₹480.41₹408.52
Total Equity & Liabilities₹1,205.14₹929.86₹830.58₹595.02

Income Statement · Standalone

Income Statement · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Revenue₹1,403.18₹1,196.42₹1,014.47₹884.05
Other Income₹10.65₹5.93₹6.46₹7.05
Total Revenue₹1,413.83₹1,202.35₹1,020.93₹891.10
Total Expenses₹1,154.58₹1,004.20₹902.46₹780.44
Profit Before Tax₹240.15₹198.15₹118.48₹110.66
Tax₹55.30₹49.10₹27.98₹25.96
Profit After Tax₹184.85₹149.05₹90.50₹84.70
EPS - Basic₹30.22₹24.37₹14.80₹14.53
EPS - Diluted₹30.22₹24.37₹14.80₹14.53

Cash Flow · Standalone

Cash Flow · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Profit before tax₹240.15₹198.15₹118.48₹110.66
Income before WC changes₹284.77₹250.84₹165.35₹133.44
Change in Assets-₹32.73-₹51.80-₹11.87-₹33.63
Change in Liabilities₹26.86₹34.73₹21.19₹28.72
Change in WC-₹5.87-₹17.07₹9.32-₹4.91
Cash flow from Operations₹229.48₹190.49₹156.76₹102.70
Cash flow from Investing-₹256.15-₹83.86-₹266.65-₹50.25
Cash flow from Financing₹25.28-₹106.57₹98.54-₹44.75
Total Cash Flow-₹1.39₹0.06-₹11.34₹7.71
Cash (Start of the year)₹3.22₹3.16₹14.49₹6.82
Cash (End of the year)₹1.83₹3.22₹3.16₹14.49

Balance Sheet · Standalone

Balance Sheet · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Non-Current Assets₹855.94₹590.37₹540.42₹303.31
Current Assets₹348.31₹338.87₹289.92₹291.49
Total Assets₹1,204.25₹929.24₹830.34₹594.80
Current Liabilities₹361.17₹239.59₹224.19₹137.37
Net Current Asset-₹12.86₹99.28₹65.73₹154.12
Non-Current Liabilities₹97.11₹83.93₹125.98₹49.13
Equity Capital₹745.97₹605.72₹480.18₹408.29
Total Equity & Liabilities₹1,204.25₹929.24₹830.34₹594.80
* All values are in INR Crore
Qty
Bid
6
2037.9
0
0
0
0
0
0
0
0
Ask
Qty
0
0
0
0
0
0
0
0
0
0
Bid Total: 6
Ask Total: 0
Buy orders: 100%
Sell orders: 0%
Bearish
4
Neutral
2
Bullish
2
Slightly Bearish
by SEBI experts
Expert Pick
EXPPICK
Stop-loss
Entry price
Target
Indicator
Value
Verdict
RSI (14)
72.61
Bullish
ATR (14)
88.67
Neutral
STOCH(9,6)
84.03
Bearish
STOCH RSI (14)
100
Bearish
ADX(9)
58.4
Bearish
UO(9)
40.44
Neutral
ROC(12)
16.41
Bullish
WillR(14)
-16.72
Bearish
Period
Simple value
Exponential vaue
5D
1987.78
1988.03
10D
1941.1
1941.08
20D
1845.21
1875.29
50D
1764.18
1781.53
100D
1671.03
1797.63

About CORONA REMEDIES LIMITED

CORONA REMEDIES LIMITED logo
ISIN
INE02ZQ01018
Sector Market Cap
₹ 12,287.1 Cr

Corona Remedies Limited is an India-based pharmaceutical formulation company. The Company is engaged in developing, manufacturing and marketing products in women’s healthcare, cardio-diabetes, pain management, urology and other/multispecialty pharmaceuticals (comprising vitamins/minerals/nutrition (VMN), gastrointestinal and respiratory). Its diverse product portfolio comprises approximately 67 brands catering to a range of therapeutic areas. It has four dosage forms in pain management formulations, which it offers in the form of tablets, capsules, sprays and injections for treatments associated with musculoskeletal spasms and diabetes. It holds brands across the women’s healthcare lifecycle, from adolescence to infertility, pregnancy, post-pregnancy and pre- and post-menopause categories. Its brands include such as C-HOP; Trazer; COR; Cortel; Rosuless; Bisobis; Sitabite; Dapabite; Fur; Voglibite; Angiwell; Stimucor; Argihope, and others.

CORONA REMEDIES LIMITED Financial Highlights

  • Revenue: CORONA REMEDIES LIMITED reported revenue of ₹1,413.83 crore in FY26 vs ₹1,202.35 crore in FY25. It showed an increase of 17.59% on a yearly basis.
  • Operating Profit: CORONA REMEDIES LIMITED reported an operating profit of ₹240.42 crore in FY26 vs ₹198.53 crore in FY25. It showed an increase of 21.10% on a year-on-year basis.
  • Net Profit: CORONA REMEDIES LIMITED reported a net profit of ₹185.12 crore in FY26 vs ₹149.43 crore in FY25. It showed an increase of 23.88% on a yearly basis.

CORONA REMEDIES LIMITED Quarterly Result Highlights

  • CORONA REMEDIES LIMITED reported revenue of ₹357.20 crore in Mar 2026, compared with ₹344.66 crore in Dec 2025, representing an increase of 3.64% on a quarter-on-quarter (QoQ) basis.
  • CORONA REMEDIES LIMITED reported an operating profit of ₹54.74 crore in Mar 2026, compared with ₹55.21 crore in Dec 2025, representing a decrease of 0.85% on a quarter-on-quarter (QoQ) basis.
  • CORONA REMEDIES LIMITED reported a profit of ₹45.33 crore in Mar 2026, compared with ₹41.27 crore in Dec 2025, reflecting an increase of 9.84% on a QoQ basis.
  • The earnings per share (EPS) of CORONA REMEDIES LIMITED stood at ₹30.27 during Mar 2026.
Know more
Promoters
69.00%
FII
2.25%
Other DII
0.67%
Retail and other
21.74%
Mutual funds
6.35%
Foreign institutions - FII
Compare against other stocks
CORONA REMEDIES LIMITED logo
CORONA REMEDIES LIMITED
Pharmaceuticals
Add Stock
Add Another

FAQs on CORONA REMEDIES LIMITED Share Price